Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo

Cancer Letters

Volumn 293, Issue 2, 2010, Pages 158-166

  Ding, Wanjing ^a   Cai, Tianyu ^a   Zhu, Hong ^a   Wu, Rui ^a   Tu, Chongxing ^a   Yang, Liuqing ^a   Lu, Wei ^b   He, Qiaojun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Apoptosis; Sunitinib; Synergism; TRAIL

Indexed keywords

FLICE INHIBITORY PROTEIN; PROTEIN MCL 1; SUNITINIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; LUNG TUMOR; MALE; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PYRROLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952467667     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.005     Document Type: Article

References (36)

1. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104:155-162.
2. Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
3. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 227:818-821.
4. Srivastava R.K. Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol. Cell. Biol. Res. Commun. 2000, 4:67-75.
5. Seol D.W., Li J., Seol M.H., Park S.Y., Talanian R.V., Billiar T.R. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res. 2001, 61:1138-1143.
6. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
7. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2003, 2:1273-1284.
8. Cartee L., Smith R., Dai Y., Rahmani M., Rosato R., Almenara J., Dent P., Grant S. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Mol. Pharmacol. 2002, 61:1313-1321.
9. Shankar S., Srivastana R.K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist. Update. 2004, 2:139-156.
10. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12:228-237.
11. Hori T., Kondo T., Kanamori M., Tabuchi Y., Ogawa R., Zhao Q.L., Ahmed K., Yasuda T., Seki S., Suzuki K., Kimura T. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 2009.
12. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003, 2:471-478.
13. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., Wong L.M., Hong W., Lee L.B., Town A., Smolich B.D., Manning W.C., Murray L.J., Heinrich M.C., Cherrington J.M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
14. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., Yuen H.A., Louie S.G., Kim H., Nicholas S., Heinrich M.C., Berdel W.E., Bello C., Jacobs M., Scigalla P., Manning W.C., Kelsey S., Cherrington J.M. An innovative phaseI clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 2003, 9:5465-5476.
15. Guérin O., Formento P., Lo Nigro C., Hofman P., Fischel J.L., Etienne-Grimaldi M.C., Merlano M., Ferrero J.M., Milano G. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J. Cancer Res. Clin. Oncol. 2008, 134:51-57.
16. Rosato R.R., Almenara J.A., Coe S., Grant S. The Multikinase Inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL downregulation. Cancer Res. 2007, 67:9490-9500.
17. Shrader M., Pino M.S., Lashinger L., Bar-Eli M., Adam L., Dinney C.P., McConkey D.J. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 2007, 67:1430-1435.
18. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regulat. 1984, 22:27-55.
19. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 1981, 115:207-216.
20. Kang M.H., Kang Y.H., Szymanska B., Wilczynska-Kalak U., Sheard M.A., Harned T.M., Lock R.B., Reynolds C.P. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110:2057-2066.
21. Ndozangue-Touriguine O., Sebbagh M., Mérino D., Micheau O., Bertoglio J., Bréard J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 2008, 27:6012-6022.
22. Poukkula M., Kaunisto A., Hietakangas V., Denessiouk K., Katajamäki T., Johnson M.S., Sistonen L., Eriksson J.E. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J. Biol. Chem. 2005, 280:27345-27355.
23. Budd R.C., Yeh W.C., Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat. Rev. Immunol. 2006, 6:196-204.
24. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002, 3:401-410.
25. Fairbrother W.J., Vucic D. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin. Cancer Res. 2007, 13:5995-6000.
26. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Gschwend J.E., Simmet T., Debatin K.M., Fulda S. Targeting XIAP Bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 2008, 68:7956-7965.
27. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., Fulda S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113:1710-1722.
28. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., Bhanot U., Hasel C., Möller P., Gschwend J.E., Simmet T., Debatin K.M., Fulda S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009, 69:2425-2434.
29. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
30. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D.J., Kaufmann S.H., Gores G.J. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64:3517-3524.
31. Wirth T., Kühnel l F., Fleischmann-Mundt B., Woller N., Djojosubroto M., Rudolph K.L., Manns M., Zender L., Kubicka S. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res. 2005, 65:7393-7402.
32. Meng X.W., Lee S.H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., Dai N.T., Kumar S.K., Smith B.D., Karp J.E., Adjei A.A., Kaufmann S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 2007, 282:29831-29846.
33. Ullenhag G.J., Mukherjee A., Watson N.F., Al-Attar A.H., Scholefield J.H., Durrant L.G. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res. 2007, 13:5070-5075.
34. Wang X., Chen W., Zeng W., Bai L., Tesfaigzi Y., Belinsky S.A., Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol. Cancer Ther. 2008, 7:1156-1163.
35. Murtaza I., Saleem M., Adhami V.M., Hafeez B.B., Mukhtar H. Suppression of cFLIP by Lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 2009, 69:1156-1165.
36. Geserick P., Drewniok C., Hupe M., Haas T.L., Diessenbacher P., Sprick M.R., Schön M.P., Henkle F., Gollnick H., Walczak H., Leverkus M. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 2008, 27:3211-3220.